The efficacy of oral beraprost sodium, a prostaglandin I2 analogue, for treating intermittent claudication in patients with arteriosclerosis obliterans

takuya matsumoto, K. Iwasa, R. Kyuragi, K. Honma, A. Guntani, T. Ohmine, H. Itoh, T. Onohara, Yoshihiko Maehara

Research output: Contribution to journalArticle

5 Citations (Scopus)

Abstract

Aim. This study aimed to evaluate the effect of oral beraprost sodium, a prostaglandin I2 analogue, on symptoms of intermittent claudication in patients with arteriosclerosis obliterans. The research design consisted of a before and after treatment study without comparison groups. The subjects comprised arteriosclerosis obliterans patients who experienced intermittent claudication. Furthermore, this study aimed to assess the mechanism of action of beraprost sodium via blood sampling and measurements of flow-mediated vasodilatation before and after treatment. Methods. The study was performed prospectively in 7 patients with arteriosclerosis obliterans. Beraprost sodium (40 μg) was orally administered to 7 patients at study entry, followed by administration of 120 μg/day for 12 weeks. Blood sampling and measurements of flow-mediated vasodilatation were performed before and after treatment at study entry, 4 weeks, and 12 weeks after treatment. Treadmill exercise tests were performed three times at study entry, 4 weeks, and 12 weeks after treatment. The ankle-brachial index (ABI) was measured at rest and after exercise. Results. Pain-free walking distances increased by 138% at 12 weeks after treatment. Maximum walking distances increased by 133%. The ABI was significantly increased at 4 weeks and 12 weeks after treatment at rest. Endothelin-1 levels tended to be decreased at 1 h after administration of 40 μg beraprost sodium. N G,NG-dimethyl-L-arginine, nitrate ions, and flow-mediated vasodilatation were not significantly changed after treatment. Conclusion. Beraprost sodium tended to decrease endothelin-1 levels and improved symptoms of intermittent claudication in patients with arteriosclerosis obliterans.

Original languageEnglish
Pages (from-to)49-54
Number of pages6
JournalInternational Angiology
Volume29
Issue number2 SUPPL. 1
Publication statusPublished - Apr 1 2010

Fingerprint

beraprost
Arteriosclerosis Obliterans
Synthetic Prostaglandins
Intermittent Claudication
Epoprostenol
Vasodilation
Ankle Brachial Index
Endothelin-1
Therapeutics
Exercise Test
Walking

All Science Journal Classification (ASJC) codes

  • Cardiology and Cardiovascular Medicine

Cite this

matsumoto, T., Iwasa, K., Kyuragi, R., Honma, K., Guntani, A., Ohmine, T., ... Maehara, Y. (2010). The efficacy of oral beraprost sodium, a prostaglandin I2 analogue, for treating intermittent claudication in patients with arteriosclerosis obliterans. International Angiology, 29(2 SUPPL. 1), 49-54.

The efficacy of oral beraprost sodium, a prostaglandin I2 analogue, for treating intermittent claudication in patients with arteriosclerosis obliterans. / matsumoto, takuya; Iwasa, K.; Kyuragi, R.; Honma, K.; Guntani, A.; Ohmine, T.; Itoh, H.; Onohara, T.; Maehara, Yoshihiko.

In: International Angiology, Vol. 29, No. 2 SUPPL. 1, 01.04.2010, p. 49-54.

Research output: Contribution to journalArticle

matsumoto, T, Iwasa, K, Kyuragi, R, Honma, K, Guntani, A, Ohmine, T, Itoh, H, Onohara, T & Maehara, Y 2010, 'The efficacy of oral beraprost sodium, a prostaglandin I2 analogue, for treating intermittent claudication in patients with arteriosclerosis obliterans', International Angiology, vol. 29, no. 2 SUPPL. 1, pp. 49-54.
matsumoto, takuya ; Iwasa, K. ; Kyuragi, R. ; Honma, K. ; Guntani, A. ; Ohmine, T. ; Itoh, H. ; Onohara, T. ; Maehara, Yoshihiko. / The efficacy of oral beraprost sodium, a prostaglandin I2 analogue, for treating intermittent claudication in patients with arteriosclerosis obliterans. In: International Angiology. 2010 ; Vol. 29, No. 2 SUPPL. 1. pp. 49-54.
@article{f17a09deb84d49738c127bf54e67afd7,
title = "The efficacy of oral beraprost sodium, a prostaglandin I2 analogue, for treating intermittent claudication in patients with arteriosclerosis obliterans",
abstract = "Aim. This study aimed to evaluate the effect of oral beraprost sodium, a prostaglandin I2 analogue, on symptoms of intermittent claudication in patients with arteriosclerosis obliterans. The research design consisted of a before and after treatment study without comparison groups. The subjects comprised arteriosclerosis obliterans patients who experienced intermittent claudication. Furthermore, this study aimed to assess the mechanism of action of beraprost sodium via blood sampling and measurements of flow-mediated vasodilatation before and after treatment. Methods. The study was performed prospectively in 7 patients with arteriosclerosis obliterans. Beraprost sodium (40 μg) was orally administered to 7 patients at study entry, followed by administration of 120 μg/day for 12 weeks. Blood sampling and measurements of flow-mediated vasodilatation were performed before and after treatment at study entry, 4 weeks, and 12 weeks after treatment. Treadmill exercise tests were performed three times at study entry, 4 weeks, and 12 weeks after treatment. The ankle-brachial index (ABI) was measured at rest and after exercise. Results. Pain-free walking distances increased by 138{\%} at 12 weeks after treatment. Maximum walking distances increased by 133{\%}. The ABI was significantly increased at 4 weeks and 12 weeks after treatment at rest. Endothelin-1 levels tended to be decreased at 1 h after administration of 40 μg beraprost sodium. N G,NG-dimethyl-L-arginine, nitrate ions, and flow-mediated vasodilatation were not significantly changed after treatment. Conclusion. Beraprost sodium tended to decrease endothelin-1 levels and improved symptoms of intermittent claudication in patients with arteriosclerosis obliterans.",
author = "takuya matsumoto and K. Iwasa and R. Kyuragi and K. Honma and A. Guntani and T. Ohmine and H. Itoh and T. Onohara and Yoshihiko Maehara",
year = "2010",
month = "4",
day = "1",
language = "English",
volume = "29",
pages = "49--54",
journal = "International Angiology",
issn = "0392-9590",
publisher = "Edizioni Minerva Medica S.p.A.",
number = "2 SUPPL. 1",

}

TY - JOUR

T1 - The efficacy of oral beraprost sodium, a prostaglandin I2 analogue, for treating intermittent claudication in patients with arteriosclerosis obliterans

AU - matsumoto, takuya

AU - Iwasa, K.

AU - Kyuragi, R.

AU - Honma, K.

AU - Guntani, A.

AU - Ohmine, T.

AU - Itoh, H.

AU - Onohara, T.

AU - Maehara, Yoshihiko

PY - 2010/4/1

Y1 - 2010/4/1

N2 - Aim. This study aimed to evaluate the effect of oral beraprost sodium, a prostaglandin I2 analogue, on symptoms of intermittent claudication in patients with arteriosclerosis obliterans. The research design consisted of a before and after treatment study without comparison groups. The subjects comprised arteriosclerosis obliterans patients who experienced intermittent claudication. Furthermore, this study aimed to assess the mechanism of action of beraprost sodium via blood sampling and measurements of flow-mediated vasodilatation before and after treatment. Methods. The study was performed prospectively in 7 patients with arteriosclerosis obliterans. Beraprost sodium (40 μg) was orally administered to 7 patients at study entry, followed by administration of 120 μg/day for 12 weeks. Blood sampling and measurements of flow-mediated vasodilatation were performed before and after treatment at study entry, 4 weeks, and 12 weeks after treatment. Treadmill exercise tests were performed three times at study entry, 4 weeks, and 12 weeks after treatment. The ankle-brachial index (ABI) was measured at rest and after exercise. Results. Pain-free walking distances increased by 138% at 12 weeks after treatment. Maximum walking distances increased by 133%. The ABI was significantly increased at 4 weeks and 12 weeks after treatment at rest. Endothelin-1 levels tended to be decreased at 1 h after administration of 40 μg beraprost sodium. N G,NG-dimethyl-L-arginine, nitrate ions, and flow-mediated vasodilatation were not significantly changed after treatment. Conclusion. Beraprost sodium tended to decrease endothelin-1 levels and improved symptoms of intermittent claudication in patients with arteriosclerosis obliterans.

AB - Aim. This study aimed to evaluate the effect of oral beraprost sodium, a prostaglandin I2 analogue, on symptoms of intermittent claudication in patients with arteriosclerosis obliterans. The research design consisted of a before and after treatment study without comparison groups. The subjects comprised arteriosclerosis obliterans patients who experienced intermittent claudication. Furthermore, this study aimed to assess the mechanism of action of beraprost sodium via blood sampling and measurements of flow-mediated vasodilatation before and after treatment. Methods. The study was performed prospectively in 7 patients with arteriosclerosis obliterans. Beraprost sodium (40 μg) was orally administered to 7 patients at study entry, followed by administration of 120 μg/day for 12 weeks. Blood sampling and measurements of flow-mediated vasodilatation were performed before and after treatment at study entry, 4 weeks, and 12 weeks after treatment. Treadmill exercise tests were performed three times at study entry, 4 weeks, and 12 weeks after treatment. The ankle-brachial index (ABI) was measured at rest and after exercise. Results. Pain-free walking distances increased by 138% at 12 weeks after treatment. Maximum walking distances increased by 133%. The ABI was significantly increased at 4 weeks and 12 weeks after treatment at rest. Endothelin-1 levels tended to be decreased at 1 h after administration of 40 μg beraprost sodium. N G,NG-dimethyl-L-arginine, nitrate ions, and flow-mediated vasodilatation were not significantly changed after treatment. Conclusion. Beraprost sodium tended to decrease endothelin-1 levels and improved symptoms of intermittent claudication in patients with arteriosclerosis obliterans.

UR - http://www.scopus.com/inward/record.url?scp=77953607651&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77953607651&partnerID=8YFLogxK

M3 - Article

C2 - 20357749

AN - SCOPUS:77953607651

VL - 29

SP - 49

EP - 54

JO - International Angiology

JF - International Angiology

SN - 0392-9590

IS - 2 SUPPL. 1

ER -